



ChemoCentryx, Inc.
 Investor Relations Department
 850 Maude Avenue
 Mountain View, CA 94043
 United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: CCXI

Last Trade:	8.83
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.95 - 9.10
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 6, 2017*
[Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis \(FSGS\)](#)
- May 24, 2017*
[ChemoCentryx to Present at Two Upcoming Investor Conferences](#)
- May 23, 2017*
[ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy \(C3G\)](#)
- May 10, 2017*
[ChemoCentryx Reports First Quarter 2017 Financial Results](#)
- Apr 27, 2017*
[ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017](#)

Financials [\[View all \]](#)

- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*
[Quarterly Report \(10-Q\)](#)